Form 4: IN8BIO, INC.: Chief Operating Officer Kate Rochlin Reports Stock Option Grant

Kate Rochlin, Chief Operating Officer of IN8BIO, INC., reports the acquisition of stock options on December 19, 2024.

Summary

• Kate Rochlin, the Chief Operating Officer of IN8BIO, INC. filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on December 19, 2024.
• Rochlin acquired 302,839 employee stock options with an exercise price of $0.24.
• These options vest on December 19, 2025, contingent upon continued service.
• The options expire on December 19, 2034.
• Following the reported transaction, Rochlin directly owns 302,839 derivative securities.

Sentiment

Score: 7

Explanation: The document indicates standard executive compensation practices, suggesting stability and alignment of interests. The sentiment is neutral to slightly positive.

Positives

• The grant of stock options to the COO aligns her interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech sector.
• The size of the grant and the vesting schedule are typical for a COO-level executive at a company of IN8BIO's size and stage of development.
• Comparable companies such as Celldex Therapeutics and Ziopharm Oncology also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The grant incentivizes the COO to work towards increasing shareholder value.

Key Dates